Irreversible Electroporation for Liver Metastases from Colorectal Cancer: A Systematic Review.
ablation
colorectal cancer
irreversible electroporation
liver metastases
systematic review
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Apr 2023
24 Apr 2023
Historique:
received:
17
03
2023
revised:
16
04
2023
accepted:
20
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
Irreversible electroporation (IRE) is a non-thermal form of ablation based on the delivery of pulsed electrical fields. It has been used to treat liver lesions, particularly those in proximity to major hepatic vasculature. The role of this technique in the portfolio of treatments for colorectal hepatic metastases has not been clearly defined. This study undertakes a systematic review of IRE for treatment of colorectal hepatic metastases. The study protocol was registered with the PROSPERO register of systematic reviews (CRD42022332866) and reports in compliance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA). The Ovid MEDLINE One hundred eighty patients underwent treatment for liver metastases from colorectal cancer. The median transverse diameter of tumours treated by IRE was <3 cm. Ninety-four (52%) tumours were adjacent to major hepatic inflow/outflow structures or the vena cava. IRE was undertaken under general anaesthesia with cardiac cycle synchronisation and with the use of either CT or ultrasound for lesion localisation. Probe spacing was less than 3.2 cm for all ablations. There were two (1.1%) procedure-related deaths in 180 patients. There was one (0.5%) post-operative haemorrhage requiring laparotomy, one (0.5%) bile leak, five (2.8%) post-procedure biliary strictures and a zero incidence of post-IRE liver failure. This systematic review shows that IRE for colorectal liver metastases can be accomplished with low procedure-related morbidity and mortality. Further prospective study is required to assess the role of IRE in the portfolio of treatments for patients with liver metastases from colorectal cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Irreversible electroporation (IRE) is a non-thermal form of ablation based on the delivery of pulsed electrical fields. It has been used to treat liver lesions, particularly those in proximity to major hepatic vasculature. The role of this technique in the portfolio of treatments for colorectal hepatic metastases has not been clearly defined. This study undertakes a systematic review of IRE for treatment of colorectal hepatic metastases.
METHODS
METHODS
The study protocol was registered with the PROSPERO register of systematic reviews (CRD42022332866) and reports in compliance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA). The Ovid MEDLINE
RESULTS
RESULTS
One hundred eighty patients underwent treatment for liver metastases from colorectal cancer. The median transverse diameter of tumours treated by IRE was <3 cm. Ninety-four (52%) tumours were adjacent to major hepatic inflow/outflow structures or the vena cava. IRE was undertaken under general anaesthesia with cardiac cycle synchronisation and with the use of either CT or ultrasound for lesion localisation. Probe spacing was less than 3.2 cm for all ablations. There were two (1.1%) procedure-related deaths in 180 patients. There was one (0.5%) post-operative haemorrhage requiring laparotomy, one (0.5%) bile leak, five (2.8%) post-procedure biliary strictures and a zero incidence of post-IRE liver failure.
CONCLUSIONS
CONCLUSIONS
This systematic review shows that IRE for colorectal liver metastases can be accomplished with low procedure-related morbidity and mortality. Further prospective study is required to assess the role of IRE in the portfolio of treatments for patients with liver metastases from colorectal cancer.
Identifiants
pubmed: 37173895
pii: cancers15092428
doi: 10.3390/cancers15092428
pmc: PMC10177346
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Vasc Interv Radiol. 2014 Jul;25(7):997-1011; quiz 1011
pubmed: 24656178
Oncotarget. 2017 Jan 24;8(4):5853-5860
pubmed: 28009979
Eur J Surg Oncol. 2020 May;46(5):772-781
pubmed: 31862133
Eur Radiol. 2021 Sep;31(9):6511-6521
pubmed: 33638687
Int J Comput Assist Radiol Surg. 2017 May;12(5):803-809
pubmed: 27653615
Nat Rev Clin Oncol. 2014 Aug;11(8):446-59
pubmed: 24889770
HPB (Oxford). 2011 Mar;13(3):168-73
pubmed: 21309933
J Vasc Interv Radiol. 2020 Nov;31(11):1765-1771.e15
pubmed: 32978054
Cardiovasc Intervent Radiol. 2020 Jan;43(1):84-93
pubmed: 31385006
J Vasc Interv Radiol. 2011 May;22(5):611-21
pubmed: 21439847
Eur J Surg Oncol. 2017 Apr;43(4):751-757
pubmed: 28109674
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
ANZ J Surg. 2003 Sep;73(9):712-6
pubmed: 12956787
Curr Oncol Rep. 2022 Jun;24(6):793-808
pubmed: 35298796
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Surg Oncol. 2020 Sep;122(3):407-411
pubmed: 32483842
Ann Oncol. 2012 Oct;23(10):2619-2626
pubmed: 22431703
Ann Oncol. 2023 Jan;34(1):10-32
pubmed: 36307056
Dig Surg. 2019;36(4):273-280
pubmed: 29886488
Eur Radiol. 2014 Oct;24(10):2467-75
pubmed: 24939670
Cardiovasc Intervent Radiol. 2015 Feb;38(1):152-9
pubmed: 24798135
Radiology. 2021 May;299(2):470-480
pubmed: 33724066
Cardiovasc Intervent Radiol. 2022 Feb;45(2):182-189
pubmed: 34757483
J Vasc Interv Radiol. 2014 Aug;25(8):1233-1239.e2
pubmed: 24861662